Want to see JP:7096 full AI Analyst Report?

StemCell Institute (7096) Price & Analysis

0 Followers

7096 Stock Chart & Stats

¥793.00

¥110.00(8.02%)

At close: Jan 08 4:00 PM EST

¥793.00

¥110.00(8.02%)

Day’s Range― - ―

52-Week Range¥627.00 - ¥1,085.00

Previous CloseN/A

Volume70.10K

Average Volume (3M)28.64K

Market Cap

¥7.67B

Enterprise Value¥5.75K

Total Cash (Recent Filing)¥2.83B

Total Debt (Recent Filing)¥473.81M

Price to Earnings (P/E)49.2

Beta0.46

Next Earnings

Aug 12, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)15.24

Shares Outstanding10,246,600

10 Day Avg. Volume23,150

30 Day Avg. Volume28,640

Financial Highlights & Ratios

PEG Ratio-0.84

Price to Book (P/B)2.88

Price to Sales (P/S)2.75

P/FCF Ratio-23.04

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)19.9

Revenue Forecast (FY)¥3.18B

Bulls Say, Bears Say

Bulls Say

Revenue Growth TrendConsistent multi-year revenue growth indicates durable end-market demand and ongoing product adoption. That steady top-line base supports predictable scale benefits, helps absorb cyclical pressures, and improves visibility for planning and investment decisions over the next 2–6 months.

High Gross MarginA sustained ~61% gross margin signals attractive unit economics and pricing power. High gross margins give structural cushion for operating leverage recovery, funding for R&D or commercialization, and resilience to input-cost shocks, supporting medium-term profitability improvement.

Healthy Balance Sheet / Modest LeverageLow-ish debt relative to equity and asset growth imply financial flexibility and lower near-term solvency risk. A generally healthy balance sheet reduces refinancing pressure, enabling continued R&D spending or selective M&A without immediate reliance on dilutive capital in the coming months.

Bears Say

Deteriorating Cash GenerationSharp OCF decline and deeply negative free cash flow materially weaken self-funding ability. This increases dependence on external capital, raises dilution or covenant risk, and constrains discretionary spending (commercialization, trials) — a structural constraint on execution over months ahead.

Sharply Weaker Profitability (2026)A precipitous drop in net margin signals loss of operating efficiency or elevated costs that erode the company’s ability to convert revenue into durable earnings. If persistent, this undermines capacity to invest and to generate returns for shareholders over the medium term.

Rising Leverage And Lower ROEAn increase in debt after years of minimal leverage, combined with falling ROE, suggests new capital is not yet producing higher returns. This elevates interest-rate and refinancing sensitivity and could amplify downside if profitability or cash flow do not recover.

StemCell Institute News

StemCell Institute Expands into Southeast Asia with Joint Venture

The latest announcement is out from StemCell Institute ( ($JP:7096) ). StemCell Institute Inc. has entered a joint...

1y ago

7096

7096 FAQ

What was StemCell Institute’s price range in the past 12 months?

StemCell Institute lowest stock price was ¥627.00 and its highest was ¥1085.00 in the past 12 months.

What is StemCell Institute’s market cap?

StemCell Institute’s market cap is ¥7.67B.

When is StemCell Institute’s upcoming earnings report date?

StemCell Institute’s upcoming earnings report date is Aug 12, 2026 which is in 21 days.

How were StemCell Institute’s earnings last quarter?

StemCell Institute released its earnings results on May 13, 2026. The company reported ¥0.94 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.

Is StemCell Institute overvalued?

According to Wall Street analysts StemCell Institute’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does StemCell Institute pay dividends?

StemCell Institute pays a Notavailable dividend of ¥25 which represents an annual dividend yield of N/A. See more information on StemCell Institute dividends here

What is StemCell Institute’s EPS estimate?

StemCell Institute’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does StemCell Institute have?

StemCell Institute has 10,246,600 shares outstanding.

What happened to StemCell Institute’s price movement after its last earnings report?

StemCell Institute reported an EPS of ¥0.94 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.37%.

Which hedge fund is a major shareholder of StemCell Institute?

Currently, no hedge funds are holding shares in JP:7096

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

StemCell Institute

StemCell Institute Inc. provides specialized stem cell banking services throughout Japan. In addition to its core preservation activities, the company is deeply involved in the research and development of medical therapies that utilize stem cells, and it also offers banking solutions for blood vessel cells. Founded in 1999, StemCell Institute Inc. is headquartered in Tokyo, Japan, and operates as a subsidiary of Trim Medical Holdings Inc.